A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Last updated: April 4, 2025
Sponsor: Bristol-Myers Squibb
Overall Status: Completed

Phase

N/A

Condition

Myelofibrosis

Post-polycythemia Vera Myelofibrosis

Treatment

N/A

Clinical Study ID

NCT05665192
CA054-1014
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosed with Primary myelofibrosis (PMF), post- Essential thrombocythemia (ET)Myelofibrosis (MF), or post- Polycythemia vera (PV) MF

  • Treated with FEDR and initiated treatment after 16 August 2019.

  • Received prior treatment with RUX.

  • Had spleen assessed at time of initiation of FEDR by palpation.

  • Able to read and speak English

  • Willing to provide informed consent

  • Willing to provide permission to the site to release her/his medical information tothe study investigators according to the study-specific eCRF

  • Willing to complete the baseline survey prior to first FEDR

Exclusion

Exclusion Criteria:

  • Past or current participant in any FEDR-related clinical trial

Study Design

Total Participants: 150
Study Start date:
August 02, 2021
Estimated Completion Date:
July 24, 2023

Connect with a study center

  • Local Institution

    City, State 00000
    Austria

    Site Not Available

  • Cardinal Health Specialty Solutions

    Dublin, Ohio 43017
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.